SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast August 5, 2019 - NASDAQ Companies 0 » View More News for August 05, 2019
